Research Library

Despite internal changes in how scientists are nominated for the Nobel Prize, there is still a substantial gender bias in prize recipients. Concrete policy changes are needed to ensure more diversity is reflected in the world’s most visible and prestigious scientific honor, write experts Kenneth M. Evans, Kirstin R.W. Matthews and Daniel Moralí. Baker Institute blog: http://bit.ly/2MDRDbW

While the U.S. still maintains the overall lead in Nobel prizes (with the exception of literature), the rate at which American scientists have been awarded the prize has declined since the late 1970s. Fellow Kirstin R.W. Matthews and postdoctoral fellow Kenneth M. Evans explore the state of scientific collaboration in the U.S. in this Baker Institute blog: https://bit.ly/2yiNhzF

High cancer drug prices reduce access to therapy, cause treatment abandonment and financial bankruptcies, as well as severe emotional and family distress.

The 340B Drug Pricing Program, which allows uninsured or low-income patients to buy prescription drugs at discounted prices, is under attack.

Baker Institute experts blog on opportunities for the U.S. and Mexico to jointly address the neglected tropical diseases found among the poorest people living in both countries.

In this commentary, the authors examine the roots of the United States’ reluctance to embrace universal health care, concluding that it "is neither sound nor ethical in a nation that promulgates fairness and equal opportunity" to deny coverage.

In physics, extensive collaborations, access to colleagues’ data and rigorous peer review make it extremely difficult for individual researchers to bend the rules. Furthermore, physics does not harbor the types of ethical minefields characteristic of the biosciences. No thorny questions arise pertaining to human or animal life, nor do physicists commonly grapple with the ethical haze of intellectual property when patents and money are at stake. Things seem to be black and white in physics. But are they?

It is inconceivable to imagine our nation today without the gains of the Civil Rights Act. It is impossible to understand why the issue was so divisive then, since it is such an obvious right and moral proposition. Similarly, let us hope we will look back at the Affordable Care Act 20 years from now and wonder why it was such a contentious topic in 2014.

Cancer drug shortages are almost uniquely associated with generic drugs (small profit margins) and rarely with patented drugs (large profit margins). They are common in the U.S., but uncommon in Europe and elsewhere, where generic drug prices are on average higher than in the U.S. This suggests the main cause of drug shortages is economic.